November 17, 2003Open Access

Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety

LPLynn PurkinsZiarco (United Kingdom)NWNolan WoodCertara (United States)KGKatie GreenhalghNewcastle University

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The oral dosing regimen selected for subsequent Phase II/III clinical trials on the basis of these results was 200 mg twice daily, equivalent to 3 mg kg-1 twice daily.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Purkins et al. (Mon,) studied this question.

synapsesocial.com/papers/69e34fdcdfa4bcab6eb73706 https://doi.org/https://doi.org/10.1046/j.1365-2125.2003.01993.x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Treatment of Infections Associated with Human Immunodeficiency Virus1988 · 202 citations
2Production of IFN-? is impaired in patients with paracoccidioidomycosis during active disease and is restored after clinical remission2000 · 156 citations
3Itraconazole1989 · 361 citations
4European experience with itraconazole in systemic mycoses1990 · 70 citations
5Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus1998 · 91 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo